Company Overview and News

 
Troy: Homer's epic returns, all sandals, swords and cheesiness

2018-09-14 smh.com.au
As every writer writer knows, sometimes the best way to find new stories is to go back to the old ones, which may explain Netflix's recent release, Troy. Co-produced with BBC One, this eight-part series explores Homer's account of the Trojan War in his epic poem, The Iliad, in which Helen, wife of the Spartan king Menelaus, runs off with Paris, a prince of Troy. Menelaus (Jonas Armstrong) goes to Troy to ask for Helen's return, but when diplomacy fails, he marshalls a fearsome group to get her back, including Odysseus (Joseph Mawle), Achilles (David Gyasi) and Agamemnon (Johnny Harris).
ILD

 
How Harry Potter grew up, became a dad and took his final encore

2018-07-27 smh.com.au
A decade after J.K. Rowling put the Harry Potter series to bed, she agreed to bring the wizard out a final time. The epic two-part stage play – soon to land in Melbourne – has won accolades worldwide.
ILD NYTAB

 
Neil deGrasse Tyson Lists 8 (Free) Books Every Intelligent Person Should Read | Open Culture

2018-07-07 openculture
A Reddit.com user posed the question to Neil deGrasse Tyson: "Which books should be read by every single intelligent person on the planet?"
STZU ILD

4
French Soccer Rights Soar as Chinese-Led Venture Outbids Canal+ - Bloomberg

2018-05-29 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BT.A BTGOF ILD VIV BT

 
Telecom Italia sales up on mobile growth

2018-05-18 thestar.com.my
MILAN: Telecom Italia SpA posted first-quarter sales that beat analysts’ estimates, driven by growth in domestic mobile and broadband subscriber numbers.
CKHUF ILD CKHUY VIV 8038

15
Vodafone boss Vittorio Colao makes way for Nick Read

2018-05-16 livemint
London: Vodafone Group Plc chief executive officer (CEO) Vittorio Colao is leaving after a decade of retreating from aggressive global growth in favour of the European market, handing the reins to company veteran Nick Read.
VOD VOD LBTY LBTYB LBTYA ICLQY 532822 DTEGF LBTYK LILAB VODPF LILAK IDEA ILD DTEGY LILA

2
Bouygues Weighs Bid With Co-Investors for Altice Unit - Bloomberg

2018-04-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ORAN ATC ORA ILD FNCTF EN

34
Bloomberg’s Week in Pictures - Bloomberg

2018-04-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
FB ILD MATX

 
Mobile Rivalry Is Keeping Down Prices in the U.K. - Bloomberg

2018-04-03 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CKHUF ILD CKHUY

 
Matt Levine Live at Bloomberg HQ (Ep. 34) – Conversations with Tyler – Medium

2018-04-02 medium
Is Matt Levine a modern-day Horace? Like Matt, Horace has a preoccupation with wealth and the law. There’s a playful humor as he segues from topic to topic. An ability to read Latin. And many of Horace’s letters are about the length of a Bloomberg View column. QED, says Tyler.
ILD

 
“Homer Can Help You”: War Veterans Use Ancient Greek Epics to Cope

2018-03-15 thenationalherald
In this Feb. 12, 2018 photo, University of Vermont student veterans Thomas Moore, left, and Dan Wright, participate in a class studying Homer's "The Iliad" and "The Odyssey" in Burlington, Vt. (AP Photo/Wilson Ring)
ILD

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:ILD / ILIAD on message board site Silicon Investor.

PAW - Pacific Wildcat Resources Corp PAW - Pacific Wildcat Resources Corp PAW - Pacific Wildcat Resources Corp TNRG Tianrong Building Materials TNRG Tianrong Building Materials TNRG Tianrong Building Materials
Bodybuilding Bodybuilding Bodybuilding Computer Building Computer Building Computer Building
Gilead Science (GILD) Followers Gilead Science (GILD) Followers Gilead Science (GILD) Followers Buffalo Wild Wings Buffalo Wild Wings Buffalo Wild Wings
Children and Investing Children and Investing Children and Investing Gilead Sciences (GILD) Gilead Sciences (GILD) Gilead Sciences (GILD)
SLJB - Sulja Brothers Building Supply, Inc. SLJB - Sulja Brothers Building Supply, Inc. SLJB - Sulja Brothers Building Supply, Inc. Building Turbines, Inc. Building Turbines, Inc. Building Turbines, Inc.